HomeWeight LossSemaglutide

Prescription Medication

Semaglutide

Semaglutide is a prescription glucagon-like peptide-1 (GLP-1) receptor agonist. [1]

Active Ingredient Research [1]

  • Reduced appetite
  • Lower calorie intake
  • Blood sugar regulation
Semaglutide Vial
$415 / 4 mL vial with Membership
Start Intake

Members only. Physician review required. Compounded semaglutide is not FDA-approved.

[1] Wegovy’s prescribing information describes these effects of semaglutide. Evidence for an FDA-approved product does not establish the same outcomes for a compounded preparation.

Explore the Research ↓

Knowledge

By GetOPT Review Team · Original article reviewed by Jeremie Walker, MD, MBA, September 15, 2026.
Updated November 4, 2026. Weight Loss Guide

Semaglutide Research

Semaglutide is a prescription GLP-1 receptor agonist that acts on appetite (Wegovy Prescribing Information). The Food and Drug Administration (FDA) approves Wegovy for chronic weight management in adults with obesity, or overweight accompanied by a weight-related condition, alongside diet and physical activity (Wegovy Prescribing Information). A prescription requires physician review. Discuss your medical history with a licensed clinician to evaluate your eligibility.

Semaglutide and Appetite

Semaglutide binds to and activates GLP-1 receptors in the body (Wegovy Prescribing Information). Semaglutide acts on appetite and calorie intake and also delays stomach emptying (Wegovy Prescribing Information). It also prompts insulin release when blood sugar rises (Wegovy Prescribing Information).

The drug is available as branded injectable Wegovy and an oral tablet formulation indicated for weight management (Wegovy Prescribing Information; Wegovy pill). Related evaluations explore GLP-1 for men and microdosing GLP-1. Review your metabolic labs with a physician to evaluate how receptor activation supports your goals.

Weight-Loss Findings

The phase 3 STEP 1 trial by Wilding and colleagues evaluated semaglutide in 1,961 adults with overweight or obesity without diabetes (PubMed PMID 33567185). Over 68 weeks alongside lifestyle intervention, participants assigned to semaglutide achieved a mean body-weight change of -14.9%, compared to -2.4% in the placebo group (Wilding et al.).

These data reflect group trial averages rather than guaranteed personal outcomes or typical Opt Health results. STEP 1 included men and women. STEP 1 did not test unapproved compounded formulations (Wilding et al.). Nausea and diarrhea were the most common adverse reactions, presenting mostly as transient, mild to moderate symptoms (Wilding et al.). Schedule a consultation with a doctor to discuss how these trial findings apply to your health history.

Semaglutide and Metformin

The STEP 1 trial compared semaglutide with placebo, so STEP 1 cannot establish a comparison with metformin (Wilding et al.).

An Opt physician reviews existing conditions and current medications at the initial consultation (Opt Health FAQ). Read the metformin guide for that medication’s separate research context. Consult your physician to evaluate which therapy aligns with your treatment plan.

Approved and Compounded Products

Branded Wegovy and compounded semaglutide differ across regulatory review, manufacturing standards, and clinical evidence (FDA Unapproved GLP-1 Statement). The U.S. Food and Drug Administration (FDA) does not review compounded drugs for safety, effectiveness, or quality before they are marketed (FDA Unapproved GLP-1 Statement).

Evaluation Criterion FDA-Approved Branded Wegovy Compounded Semaglutide
Regulatory Status FDA approved for weight management Not FDA approved or reviewed before marketing
Product Identity Verified manufacturer formulation Individual compounded preparation
Clinical Evidence Supported by randomized clinical trials Not tested in the cited STEP 1 trial
Clinical Role Labeled indications inform physician review Considered when approved drugs do not meet needs

The FDA notes that compounded drugs should be used only when approved options cannot meet a patient's medical needs (FDA Unapproved GLP-1 Statement). For related comparisons, see our review of semaglutide vs tirzepatide or compounded semaglutide. Ask your prescriber to confirm the regulatory status and identity of your medication.

Semaglutide Costs

Understanding weight management costs requires separating clinical membership fees from medication fulfillment charges (GLP-1 Cost). An Opt Health Foundation membership covers diagnostic testing and ongoing physician oversight, while medication is billed separately through our pharmacy if prescribed (Opt Health Memberships). Review the membership fee and any medication charge separately before starting care.

Medication prices vary by product identity and pharmacy source, and insurance policies differ widely (GLP-1 Cost). The telehealth weight loss program explains the care process alongside medication questions. Review your plan details with an Opt Health care coordinator before starting care.

Side Effects and Medical Review

Common adverse reactions to semaglutide include: (Wegovy Prescribing Information; GLP-1 Hair Loss).

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach pain
  • Headache
  • Fatigue
  • Indigestion
  • Dizziness
  • Abdominal distension
  • Belching
  • Gas
  • Low blood sugar in type 2 diabetes
  • Gastroenteritis
  • Reflux
  • Hair loss

Serious Warnings

Serious warnings include: (Wegovy Prescribing Information).

  • Acute pancreatitis
  • Gallbladder disease
  • Acute kidney injury from volume depletion
  • Severe gastrointestinal reactions
  • Hypersensitivity
  • Diabetic retinopathy complications
  • Increased heart rate
  • Aspiration during anesthesia

A boxed warning notes that semaglutide causes thyroid C-cell tumors in rodents, though human risk is unknown (Wegovy Prescribing Information). The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with known hypersensitivity (Wegovy Prescribing Information). Wegovy is also not recommended for individuals with severe gastroparesis (Wegovy Prescribing Information). Report persistent gastrointestinal symptoms to your physician to receive personalized clinical guidance.

Gallbladder and Cardiovascular Findings

Clinical trials showed an increased rate of acute gallbladder events, such as cholelithiasis, which are associated with significant weight loss (Wegovy Prescribing Information). Patients experiencing severe abdominal pain radiating to the back need prompt medical review to evaluate for gallbladder disease or pancreatitis (Wegovy Prescribing Information).

Cardiovascular labeling is restricted to adults with established cardiovascular disease and obesity or overweight to reduce the risk of major adverse cardiovascular events (Wegovy Prescribing Information). These Wegovy findings do not establish general cardiovascular prevention or cardiovascular outcomes for compounded semaglutide. For questions about cancer, a medication's warning list cannot settle personal cancer risk, including breast cancer; discuss medical history with a clinician instead (Wegovy Prescribing Information). Review your personal and family history with your doctor.

The Opt Take on Semaglutide

At Opt Health, we evaluate weight management through comprehensive metabolic and hormonal biomarkers rather than appetite suppression alone (Opt Health Lose Weight). Deciding to register for an intake panel is distinct from a physician deciding to prescribe medication (Opt Health Memberships). An initial panel evaluates 55+ biomarkers, followed by a 60-minute physician consultation to review existing conditions and current medications (Opt Health Memberships).

Under the Foundation membership, follow-up labs and physician reviews repeat twice per year to measure objective progress (Opt Health Memberships). Contraindications, clinical lab findings, product identity, and total recurring costs determine whether medical treatment is appropriate.

If you are seeking medication without a medical evaluation, the FDA recommends obtaining a prescription from your doctor before filling it at a state-licensed pharmacy.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

Who Is Eligible for a Semaglutide Prescription?

Wegovy is labeled for weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity (Wegovy Prescribing Information). A licensed physician reviews your medical history, current medications, and blood biomarkers to verify whether treatment is clinically appropriate (Opt Health Memberships). Book an intake consultation to review your health indicators with a doctor.

Is Compounded Semaglutide Approved by the FDA?

Compounded semaglutide is not FDA-approved, and the agency does not review it for safety, effectiveness, or quality before it is marketed (FDA Unapproved GLP-1 Statement). The FDA recommends using compounded drugs only when an approved medication cannot meet a patient's documented clinical needs (FDA Unapproved GLP-1 Statement). Discuss medication sourcing with your clinician to make an informed choice.

What Weight Loss Can an Individual Expect on Semaglutide?

In the STEP 1 trial, adults without diabetes who combined semaglutide with lifestyle intervention achieved a mean body-weight reduction of 14.9% over 68 weeks (Wilding et al.). A group average cannot predict your individual result. Consult your physician to discuss realistic metabolic targets based on your labs.

How Do Membership Fees and Medication Costs Work Together?

An Opt Health Foundation membership costs $95 monthly after a $195 intake fee, covering comprehensive diagnostic panels and semi-annual physician visits (Opt Health Memberships). Prescribed medications incur separate pharmacy charges and are dispensed only after physician review and approval (Opt Health Memberships). Speak with our care team to review transparent billing details for your evaluation.

An Opt Health membership provides the physician oversight, comprehensive lab panels, and regular consultations used to review your health over time. Review our membership options to schedule your comprehensive diagnostic evaluation.

References

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.

Start Today

Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.